[4,5′]Bipyrimidinyl-6,4′-diamine derivatives as protein kinase inhibitors

US8026243B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Pamela Albaugh · Carmel, US
• Yun He · San Diego, US
• Songchun Jiang · San Diego, US
• Pingda Ren · San Diego, US
• Xia Wang · San Diego, US
• Xing Wang · San Diego, US
• Yongping Xie · San Diego, US

Key dates

• Filing date: Jul 10, 2007
• Grant date: Sep 27, 2011
• Expiry date: Jan 5, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D401/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides a novel class of compounds of the Formula I:in which the symbols have the meanings given in the description and claims, to pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of FGFR3 kinase.